Associated Papers
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
35690785 (PubMed )
Supplement: 13045_2022_1299_MOESM2_ESM.pdf
The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.
Egile C et al.
Molecular Cancer Therapeutics, 2015
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Yan SB et al.
Investigational New Drugs, 2013
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL et al.
Biochemistry, 2009
Select a paper to view details